pharma news today obesity drugs glp-1 GLP-1s: Weight loss pose risk to pharma, report finds glp-1 latest analogs, new trend

A cerium-based MOFzyme with multi-enzyme-like activity for the disruption and inhibition of fungal recolonization

Recent survey data reveal that a substantial proportion of the public continues to attribute excess weight to personal responsibility, while a growing segment supports disease classification for obesity

These bioactivities not only provide mechanistic insights into the physiological relevance of collagen peptides but also serve as the foundation for their integration into functional foods targeting oxidative stress, hypertension, and metabolic disorders

PMID: 25815981 Disclaimer: This article is for informational and educational purposes only

An antioxidant specifically targeting mitochondria delays progression of Alzheimer's disease-like pathology